Ratings by Wedbush (Andreas Argyrides)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/2/2026 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/17/2024 | Aerovate Therapeutics Inc | AVTE | Downgrade | Neutral (Outperform) |
24.62 (2.68) |
-89.11% | Details | |
| 3/13/2024 | Clearside Biomedical | CLSD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2024 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2023 | Sarepta Therapeutics | SRPT | New Coverage | Outperform (N/A) |
83.15 (20.21) |
-75.69% | Details | |
| 11/16/2023 | Moonlake Immunotherapeutics | MLTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/16/2023 | Unity Biotechnology Inc | UBX | Upgrade | Outperform (Neutral) |
1.83 (0.20) |
-89.07% | Details | |
| 11/14/2023 | Kala Pharmaceuticals | KALA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2023 | Regenxbio Inc. | RGNX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/13/2023 | ARS Pharmaceuticals Inc | SPRY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2023 | Sangamo BioSciences | SGMO | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2023 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/10/2023 | Immunic Inc. | IMUX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/10/2023 | MannKind | MNKD | New Coverage | Outperform (N/A) |
4.01 (4.25) |
5.99% | Details | |
| 9/21/2023 | ARS Pharmaceuticals Inc | SPRY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2023 | Sangamo BioSciences | SGMO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2023 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 7/31/2023 | Keros Therapeutics | KROS | New Coverage | Outperform (N/A) |
41.97 (11.67) |
-72.19% | Details | |
| 7/3/2023 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 6/30/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 6/26/2023 | Unity Biotechnology Inc | UBX | Downgrade | Neutral (Outperform) |
3.25 (0.20) |
-93.85% | Details | |
| 4/28/2023 | Oculis Holding AG | OCS | New Coverage | Outperform (N/A) |
10.86 (13.70) |
26.15% | Details | |
| 4/25/2023 | Unity Biotechnology Inc | UBX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/28/2023 | Unity Biotechnology Inc | UBX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/22/2023 | Moonlake Immunotherapeutics | MLTX | New Coverage | Outperform (N/A) |
22.01 (19.07) |
-13.36% | Details | |
| 3/9/2023 | Aquestive Therapeutics | AQST | Upgrade | Outperform (Neutral) |
0.85 (4.31) |
407.06% | Details | |
| 2/28/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/27/2023 | Sangamo BioSciences | SGMO | Upgrade | Outperform (Neutral) |
2.66 (0.18) |
-93.23% | Details | |
| 1/31/2023 | Pacira Pharmaceuticals | PCRX | New Coverage | Outperform (N/A) |
38.88 (25.52) |
-34.36% | Details | |
| 1/31/2023 | Aquestive Therapeutics | AQST | New Coverage | Neutral (N/A) |
0.88 (4.31) |
389.77% | Details | |
| 1/31/2023 | ARS Pharmaceuticals Inc | SPRY | New Coverage | Outperform (N/A) |
6.34 (8.10) |
27.76% | Details | |
| 1/31/2023 | Immunic Inc. | IMUX | New Coverage | Outperform (N/A) |
2.10 (14.77) |
603.33% | Details | |
| 12/20/2022 | Verona Pharma | VRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/12/2022 | Aerovate Therapeutics Inc | AVTE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2022 | Clearside Biomedical | CLSD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2022 | Kala Pharmaceuticals | KALA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2022 | Unity Biotechnology Inc | UBX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/19/2022 | United Therapeutics Corp. | UTHR | New Coverage | Outperform (N/A) |
218.11 (554.34) |
154.16% | Details | |
| 9/19/2022 | Liquidia Technologies | LQDA | New Coverage | Underperform (N/A) |
5.99 (79.47) |
1226.71% | Details | |
| 9/19/2022 | Gossamer Bio Inc. | GOSS | New Coverage | Outperform (N/A) |
13.52 (0.17) |
-98.74% | Details | |
| 9/19/2022 | Verona Pharma | VRNA | New Coverage | Outperform (N/A) |
10.19 (106.91) |
949.17% | Details | |
| 9/19/2022 | Aerovate Therapeutics Inc | AVTE | New Coverage | Outperform (N/A) |
15.73 (2.68) |
-82.96% | Details | |
| 6/13/2022 | Rani Therapeutics Holdsing s | RANI | New Coverage | Outperform (N/A) |
9.40 (0.69) |
-92.66% | Details | |
| 6/13/2022 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Neutral (N/A) |
75.08 (59.75) |
-20.42% | Details | |
| 6/13/2022 | Sangamo BioSciences | SGMO | New Coverage | Neutral (N/A) |
3.76 (0.18) |
-95.21% | Details | |
| 12/15/2021 | Unity Biotechnology Inc | UBX | New Coverage | Outperform (N/A) |
1.57 (0.20) |
-87.26% | Details | |
| 12/15/2021 | Graybug Vision | GRAY | New Coverage | Neutral (N/A) |
1.87 (5.50) |
194.12% | Details | |
| 12/15/2021 | Kala Pharmaceuticals | KALA | New Coverage | Outperform (N/A) |
1.45 (1.39) |
-4.14% | Details | |
| 12/15/2021 | Regenxbio Inc. | RGNX | New Coverage | Neutral (N/A) |
32.22 (15.23) |
-52.73% | Details | |
| 12/15/2021 | Clearside Biomedical | CLSD | New Coverage | Outperform (N/A) |
2.84 (0.41) |
-85.56% | Details |
